Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP
The human T-cell lymphotropic virus type 1 (HTLV-1) is the known causative agent of a chronic neurologic condition known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although several therapies have been evaluated for HAM/TSP, none have been approved for use in humans. In t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Neurological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/958786 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162227268550656 |
|---|---|
| author | Davi Tanajura Costa Michael Sundberg Lúcia Passos André Luiz Muniz Silvane Santos |
| author_facet | Davi Tanajura Costa Michael Sundberg Lúcia Passos André Luiz Muniz Silvane Santos |
| author_sort | Davi Tanajura Costa |
| collection | DOAJ |
| description | The human T-cell lymphotropic virus type 1 (HTLV-1) is the known causative agent of a chronic neurologic condition known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although several therapies have been evaluated for HAM/TSP, none have been approved for use in humans. In this paper, we describe a 55-year-old female patient with HAM/TSP who was treated with interferon beta-1a. This patient, in comparison to 20 female patients with HAM/TSP who were not treated, showed improvement in urinary symptoms over four years of therapy, as well as a reduction in HTLV-1 proviral load and serum cytokine levels typically observed in HAM/TSP. This improved outcome merits further controlled studies on the use and efficacy of interferon beta-1a as a therapy for HAM/TSP. |
| format | Article |
| id | doaj-art-fa9147dfd28b48e89db81d06c07df1fc |
| institution | OA Journals |
| issn | 2090-6668 2090-6676 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Neurological Medicine |
| spelling | doaj-art-fa9147dfd28b48e89db81d06c07df1fc2025-08-20T02:22:37ZengWileyCase Reports in Neurological Medicine2090-66682090-66762012-01-01201210.1155/2012/958786958786Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSPDavi Tanajura Costa0Michael Sundberg1Lúcia Passos2André Luiz Muniz3Silvane Santos4Serviço de Imunologia, Hospital Universitário Prof. Edgard Santos, 5 Andar, Rua João das Botas S/N, Canela, 40110-160 Salvador, BA, BrazilServiço de Imunologia, Hospital Universitário Prof. Edgard Santos, 5 Andar, Rua João das Botas S/N, Canela, 40110-160 Salvador, BA, BrazilServiço de Imunologia, Hospital Universitário Prof. Edgard Santos, 5 Andar, Rua João das Botas S/N, Canela, 40110-160 Salvador, BA, BrazilServiço de Imunologia, Hospital Universitário Prof. Edgard Santos, 5 Andar, Rua João das Botas S/N, Canela, 40110-160 Salvador, BA, BrazilServiço de Imunologia, Hospital Universitário Prof. Edgard Santos, 5 Andar, Rua João das Botas S/N, Canela, 40110-160 Salvador, BA, BrazilThe human T-cell lymphotropic virus type 1 (HTLV-1) is the known causative agent of a chronic neurologic condition known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although several therapies have been evaluated for HAM/TSP, none have been approved for use in humans. In this paper, we describe a 55-year-old female patient with HAM/TSP who was treated with interferon beta-1a. This patient, in comparison to 20 female patients with HAM/TSP who were not treated, showed improvement in urinary symptoms over four years of therapy, as well as a reduction in HTLV-1 proviral load and serum cytokine levels typically observed in HAM/TSP. This improved outcome merits further controlled studies on the use and efficacy of interferon beta-1a as a therapy for HAM/TSP.http://dx.doi.org/10.1155/2012/958786 |
| spellingShingle | Davi Tanajura Costa Michael Sundberg Lúcia Passos André Luiz Muniz Silvane Santos Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP Case Reports in Neurological Medicine |
| title | Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral
Load, and Modifies the Immune Response in a Patient with HAM/TSP |
| title_full | Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral
Load, and Modifies the Immune Response in a Patient with HAM/TSP |
| title_fullStr | Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral
Load, and Modifies the Immune Response in a Patient with HAM/TSP |
| title_full_unstemmed | Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral
Load, and Modifies the Immune Response in a Patient with HAM/TSP |
| title_short | Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral
Load, and Modifies the Immune Response in a Patient with HAM/TSP |
| title_sort | interferon beta 1a improves urinary symptoms reduces proviral load and modifies the immune response in a patient with ham tsp |
| url | http://dx.doi.org/10.1155/2012/958786 |
| work_keys_str_mv | AT davitanajuracosta interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp AT michaelsundberg interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp AT luciapassos interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp AT andreluizmuniz interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp AT silvanesantos interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp |